

Table E1: AEFI reported within 2 hours of LAIV administration

Study ID number	Time to symptoms (minutes)	Description of events	IDMC review: possible allergic aetiology?	Causality
BR/005	20-60	Generalised urticarial following LAIV. Negative allergy testing and tolerated 2 nd dose of LAIV. Reaction attributed to milk present in ingredients of snack eaten following 1 st dose of LAIV (child has milk allergy).	NO	
CA/011	5-20	Red itchy nose	YES	Probable
ED/054	5-20	Itchy naso-oropharynx. Facial flushing; no hives	YES	Probable
LE/005	5-20	Felt as if wanted to sneeze, but no actual sneezing. No significant change in TNSS.	NO	
LE/020	5-20	Pre-existing nasal symptoms due to mild cold.	NO	
LP/001	5-20	Large hive on face-disappeared in minutes. Scratching both sides of face, transient	YES	Possible
LP/016	20-60	Itchy erythema/ hives on forehead; eczema flare on arms 30 mins post LAIV	YES	Probable
NW/018	20-60	Local rhinitis symptoms at 30 mins post LAIV	YES	Possible
OX/006	1-5	Itchy nose and skin - ?due to contact reaction, no visible urticaria	YES	Possible
OX/020	20-60	Single episode of vomiting, 45 mins after LAIV. Does not meet BCC criteria for systemic reaction.	NO	
OX/022	5-20	Contact urticarial reaction	YES	Probable
RL/031	5-20	Mother reported mild R facial swelling. Negative allergy testing and tolerated 2 nd dose of LAIV without any similar symptoms.	NO	
SF/025	20-60	3 hives on chin 25 mins post LAIV, resolved in <15mins	YES	Probable
UC/006	5-20	Mild nasal itch, no change in TNSS. No objective symptoms. Tolerated 2 nd dose without issue.	NO	
UC/001	60-120	Itchy tongue and neck	YES	Possible
SM/066	20-60	Sore 'tummy' 40mins post LAIV, onset shortly after eating a take-away from local restaurant. Family member (not receiving LAIV) had same symptoms.	NO	
MA/023	60-120	Not Itchy	NO	

Table E2: Incidence of AEFI of allergic aetiology, by factor of interest.

Factor	Level	n/N	P value
Age group (years)	2-4	5/360 (1.4%)	0.24
	5-11	2/334 (0.6%)	
	12-18	2/85 (2.4%)	
Physician-assessed clinical reaction to egg in previous 12 months	No	4/464 (0.9%)	0.50
	Yes	5/315 (1.6%)	
95% PPV criteria met for egg allergy within previous 12months	No	3/326 (0.9%)	0.74
	Yes	6/453 (1.3%)	
Previous anaphylaxis to egg	No	7/622 (1.1%)	1.00
	Yes	2/157 (1.3%)	
Previous reported reaction to aerosolised egg	No	6/709 (0.8%)	0.04
	Yes	3/70 (4.3%)	
Tolerance to baked egg in diet	No	5/436 (1.1%)	1.00
	Yes	4/343 (1.2%)	
Previous influenza vaccine (any)	No	3/410 (0.7%)	0.32
	Yes	6/369 (1.6%)	
Previous LAIV	No	7/591 (1.2%)	1.00
	Yes	2/188 (1.1%)	
Diagnosis of asthma or recurrent wheeze	No	3/334 (0.9%)	0.74
	Yes	6/445 (1.3%)	
Batch ovalbumin content >1.0 ng/ml	No	2/268 (0.7%)	0.73
	Yes	7/511 (1.4%)	
Batch ovalbumin content >0.3 ng/ml	No	1/112 (0.9%)	1.00
	Yes	8/667 (1.2%)	

Table E3: Incidence of delayed events within 72 hours of LAIV administration, by factor of interest.

Factor	Level	n/N	P
Age group (years)	2-4	112/360 (0.3%)	0.07
	5-11	93/334 (0.3%)	
	12-18	16/85 (18.8%)	
Physician-assessed clinical reaction to egg in previous 12 months	No	140/464 (30.2%)	0.20
	Yes	81/315 (25.7%)	
95% PPV criteria met for egg allergy within previous 12 months	No	101/326 (31.0%)	0.17
	Yes	120/453 (26.5%)	
Previous anaphylaxis to egg	No	180/622 (28.9%)	0.55
	Yes	41/157 (26.1%)	
Previous reported reaction to aerosolised egg	No	199/709 (28.1%)	0.58
	Yes	22/70 (31.4%)	
Tolerance to baked egg in diet	No	120/436 (27.5%)	0.58
	Yes	101/343 (29.4%)	
Previous influenza vaccine (any)	No	123/410 (30.0%)	0.30
	Yes	98/369 (26.6%)	
Previous LAIV	No	176/591 (29.8%)	0.14
	Yes	45/188 (23.9%)	
Diagnosis of asthma or recurrent wheeze	No	92/334 (27.5%)	0.69
	Yes	129/445 (29.0%)	
Batch ovalbumin content >1.0 ng/ml	No	80/268 (29.9%)	0.51
	Yes	141/511 (27.6%)	
Batch ovalbumin content >0.3 ng/ml	No	28/112 (25.0%)	0.43
	Yes	193/667 (28.9%)	